Drug intelligence / Profile preview

HUFF01

Development stage: Unknown
Lead developer: Hokkaido University Hospital
Modality: Stem Cell Therapies → Cell Therapies

Overview

HUFF01 is an autologous bone marrow-derived stem cell therapy being developed by Rainbow for chronic phase cerebral hemorrhage. It is a regenerative cell therapy product that uses a patient's own bone marrow-derived stem cells with the intended goal of promoting neural and tissue repair, engraftment, and functional recovery after intracerebral hemorrhagic stroke in the chronic stage. Based on Rainbow's pipeline, HUFF01 is in Phase 1 development in Japan, and no discrete molecular target has been publicly specified.

Other names: autologous bone marrow-derived stem cells

Beyond the preview

Go deeper on HUFF01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUFF01.

Explore the full profile